[<sup>177</sup>Lu]Lu-PSMA-617 Therapy in a Patient with Chronic Kidney Disease.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 37620052.
- Also identified by DOI 10.2967/jnumed.123.265577.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We report the dosimetric evaluation of prostate-specific membrane antigen-based radioligand therapy (RLT) for metastatic prostate cancer in a patient with autosomal-dominant polycystic kidney disease. <b>Methods:</b> The patient received hemodialysis during each of 6 RLT cycles while staying as an inpatient. We used voxel dosimetry and blood sampling for the dose calculation. <b>Results:</b> The patient responded well to the RLT, as indicated by the prostate-specific antigen level decreasing from 298 to 7.1 ng/mL. The doses per cycle ranged from 0.19 to 0.4 Gy/GBq for the parotid gland, 0.14 to 0.28 Gy/GBq for the submandibular gland, 0.03 to 0.11 Gy/GBq per kidney, and 0.10 to 0.15 Gy/GBq for the red bone marrow. <b>Conclusion:</b> This case suggests that [<sup>177</sup>Lu]Lu-PSMA-based RLT can be applied successfully and safely to a patient with chronic kidney disease undergoing hemodialysis.
Medical subject headings
- Lutetium
- Heterocyclic Compounds, 1-Ring
- Renal Insufficiency, Chronic
- Prostatic Neoplasms
- Dipeptides